Fresenius Medical Care ADR earnings beat by $0.65, revenue fell short of estimates

Fresenius SE sold 13.4 million shares of Fresenius Medical Care for €524 million, reducing its stake to about 20%. The sale, at €39 per share, aims to support growth investments. Proceeds will boost book profit by a low-to-mid double-digit million euros in Q4 2026. The retained shares have a 90-day lockup.

Fresenius SE reduced its stake in Fresenius Medical Care to 20% from 25%, causing FMS shares to rise in premarket trading. The parent company announced the change in a statement.

Washington state sued DaVita and Fresenius Medical Care, alleging they suppress competition by requiring nephrologists to sign noncompete agreements, reducing patient treatment options. The state seeks to void these agreements and impose fines. DaVita denies wrongdoing; Fresenius did not comment. The FTC is also investigating. DaVita operates 51 centers in Washington, Fresenius 29, with some areas having only one provider.

Fresenius Medical Care issued a €500M bond with a 4.250% coupon, 4.363% yield, maturing in February 2032. Proceeds will refinance debt, settling November 16, 2026. The bond will list on the Luxembourg Stock Exchange.

Barclays downgraded Fresenius Medical (FMS) from Equal Weight to Underweight, signaling a bearish outlook on the stock. The company's stock has shown mixed reactions to past headlines, with a median move of 1.4% in either direction.

Fresenius Medical Care (FMS) reported stable Q3 2026 revenue despite TDAPA reimbursement challenges. The 5008X CAREsystem rollout is ahead of schedule, with 348 clinics converted and 9,000 machines installed. HighVolumeHDF treatments reached 300,000, and the Value-Based Care segment turned profitable. However, operating income declined 6% due to TDAPA headwinds and inflation.